CRA International stock adds life sciences leadership with Hillan appointment

Published on 10/05/2026 at 22:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CRA International stock has a new life sciences executive after Q2 revenue reached USD 210.81 million versus USD 198.91 million consensus. Two analysts set a USD 245 target.

CRAI, US12618T1051, Illustration mit AI erstellt.

CRA International stock (ISIN US12618T1051) was last at USD 171.29 on Nasdaq on October 5, 2026, up 0.53 percent from the prior close. The company added Patrick Hillan as vice president for life sciences commercial strategy on September 29, a move that expands its leadership in a practice tied to pharmaceutical and healthcare clients.

Life sciences leadership expands

CRA International listed the Hillan appointment among its September 2026 news releases. The role adds commercial strategy expertise to a business that already combines economic, financial and management consulting for corporations, law firms and governments.

The appointment followed an October 1 announcement that CRA added Harvard Business School Professor Feng Zhu as an academic affiliate to its Antitrust and Competition Economics Practice. That release also highlighted Zhu's work on platform economics and competition matters, linking the firm's growth agenda to complex regulatory and technology assignments.

Q2 revenue beat estimates

CRA's latest reported quarter delivered USD 210.81 million in revenue against USD 198.91 million expected, while EPS reached USD 2.16 versus a USD 2.15 consensus estimate, MarketBeat reported. The revenue beat was USD 11.90 million, giving the operating update more weight than the management appointments alone.

The same report said CRA paid a quarterly dividend of USD 0.57 on September 14, 2026. For investors, the combination of higher quarterly sales and added life sciences expertise points to two measurable parts of the story: near-term execution and deeper specialist coverage.

Analyst target stays above stock

Markets Insider reported on October 1 that Barrington analyst Kevin Steinke maintained a Buy rating and a USD 245.00 price target. The report also described CRAI's consensus as Moderate Buy with an average target of USD 245.00.

MarketBeat counted two analysts in that consensus. The average target lies 43.0 percent above the USD 171.29 Nasdaq price, while CRAI's 52-week range runs from USD 132.17 to USD 227.29.

CRAI stock stays below yearly high

CRAI was last at USD 171.29 on Nasdaq at 4:00 p.m. ET on October 5, 2026, with volume of 88,238 shares and a market capitalization of USD 1.1 billion. The stock remains USD 56.00 below its 52-week high, leaving the analyst target and the recent revenue beat as the clearest numerical reference points for the next report.